I speculate that RAC have a background activity working on an oral formulation combining Zantrene and ASTX727 (note ASTX747 is a typo).
https://www.asx.com.au/asxpdf/20211101/pdf/452fm1vcm8f2j0.pdf
https://astx.com/research-developme...azuridine-astx727-hematological-malignancies/
Otsuka have their own program developing an oral combination - from the above link:
So I'm wondering if there will be an oral formulation combining decitabine, cedazuridine and Zantrene once data to help determine optimal dosage is generated.
Ann: Race investor briefing & updated presentation, page-335
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
-0.045(2.80%) |
Mkt cap ! $272.6M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.55 | $414.6K | 257.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 375 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 950 | 1 |
View Market Depth
| Last trade - 11.34am 30/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |